Tumor hypoxia is a therapeutic target in soft-tissue sarcoma.

Abstract

TH-302 shows antitumor activity in combination with doxorubicin in advanced soft-tissue sarcoma.

• Journal: Cancer discovery (Cancer Discov) Vol. 4 Issue 11 Pg. OF21 (Nov 2014) ISSN: 2159-8290 [Electronic] United States
• PMID: 25367963 (Publication Type: Clinical Trial, Phase II, Journal Article)
• Copyright: ©2014 American Association for Cancer Research.

Chemical References

• Nitroimidazoles
• Phosphoramide Mustards
• TH 302
• Doxorubicin

Topics

• Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
• Cell Hypoxia
• Doxorubicin (administration & dosage, adverse effects)
• Humans
• Nitroimidazoles (administration & dosage, adverse effects)
• Phosphoramide Mustards (administration & dosage, adverse effects)
• Sarcoma (drug therapy)
• Tumor Microenvironment (drug effects)